Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 21% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lymphomapatientcancerradiationhodgkin
  Phrases that lowered it: myelomafemalesubjectsmalevelcade
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Collaborators: 3 (lowers risk) · Design
• Sponsor's past termination rate: 9.4% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.0% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor's past trials: 128 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 56 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 8226 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 92.2% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma NCT00671112 · started 2008 · scored riskier than 59% of active trials terminated
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma NCT00711828 · started 2008 · scored riskier than 55% of active trials completed
• A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 NCT03255096 · started 2017 · scored riskier than 30% of active trials completed
• Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL NCT02987400 · started 2017 · scored riskier than 91% of active trials completed
• Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy NCT05065866 · started 2021 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.